Skip to Content
Alumni profile

New help for a health problem women don’t talk about

Gloria Ro Kolb ’94
Gloria Kolb
Gloria Kolb
Courtesy Photo

In 2004, Gloria Ro Kolb ’94 was leading her first startup, Fossa Medical, which developed therapies for kidney stones, when she learned a startling statistic: one in three women over 30 deals with urinary incontinence. However, it wasn’t until Kolb had three kids that she began to understand the scope of the problem—and the need for a better solution. “I looked into all the treatment options and thought, ‘Oh my gosh, there’s got to be something better,’” she recalls. So she took matters into her own hands by founding the medical-device company Elidah.

Traditional treatments for urinary incontinence in women have been limited to pelvic floor exercises, invasive devices, or—in extreme cases—surgery. Moreover, many women are hesitant to discuss the issue with a doctor. “Women wait so long that it gets harder and harder for them to treat conservatively, and it really does start to affect their quality of life,” Kolb explains.

With Kolb as CEO, the Connecticut-based company has developed Elitone, a noninvasive device composed of a small electrical controller connected to a gel pad. The device, typically worn for 20 minutes four to five days a week, decreases bladder leaks by stimulating and strengthening a woman’s pelvic floor muscles—essentially doing Kegel exercises for her, but longer and stronger than she could, Kolb explains.  

Elitone was cleared by the US Food and Drug Administration in 2019 for both prescription and over-the-counter use. “Two-thirds of women won’t talk to their doctor about this—that’s how secret and private it is—so we wanted to reach out to the women directly,” Kolb says. “This is a new and growing category of direct-to-consumer medical devices.”

While FDA approval is a big milestone, Kolb finds the most satisfaction in emails from women describing their return to daily activities like dancing or running. “This is why we do what we do—because it helps,” she says. Now, the company is developing a version of Elitone for the related issue of overactive bladder. It is also investigating whether a similar device can be developed for men. 

“MIT is a good foundation for figuring out how to do things well and how to do them on your own,” says Kolb, who majored in mechanical engineering. At Elidah, she has taken on everything from designing and building prototypes to writing patents and regulatory documents. And she is eager for more opportunities to invent as she remains focused on her overarching goal: “Helping as many people as I can with the products that I make.”

Keep Reading

Most Popular

still from Embodied Intelligence video
still from Embodied Intelligence video

These weird virtual creatures evolve their bodies to solve problems

They show how intelligence and body plans are closely linked—and could unlock AI for robots.

pig kidney transplant surgery
pig kidney transplant surgery

Surgeons have successfully tested a pig’s kidney in a human patient

The test, in a brain-dead patient, was very short but represents a milestone in the long quest to use animal organs in human transplants.

conceptual illustration showing various women's faces being scanned
conceptual illustration showing various women's faces being scanned

A horrifying new AI app swaps women into porn videos with a click

Deepfake researchers have long feared the day this would arrive.

thermal image of young woman wearing mask
thermal image of young woman wearing mask

The covid tech that is intimately tied to China’s surveillance state

Heat-sensing cameras and face recognition systems may help fight covid-19—but they also make us complicit in the high-tech oppression of Uyghurs.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.